Last reviewed · How we verify
HRS-4508 tablet
HRS-4508 tablet is a Small molecule Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 2 development for Unknown.
HRS-4508 tablet is a small molecule drug that targets the molecular target.
HRS-4508 is a small molecule tablet being studied in a clinical trial for its efficacy and safety in treating locally advanced or metastatic non-small cell lung cancer. The trial is focused on solid tumor and lung cancer conditions.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | HRS-4508 tablet |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Small molecule |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Unknown |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of HRS-4508 tablet is not well understood, but it is believed to work by interacting with the molecular target, leading to a therapeutic effect.
Approved indications
- Unknown
Common side effects
- Unknown
Key clinical trials
- A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE2)
- A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-4508 tablet CI brief — competitive landscape report
- HRS-4508 tablet updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about HRS-4508 tablet
What is HRS-4508 tablet?
How does HRS-4508 tablet work?
What is HRS-4508 tablet used for?
Who makes HRS-4508 tablet?
What drug class is HRS-4508 tablet in?
What development phase is HRS-4508 tablet in?
What are the side effects of HRS-4508 tablet?
What does HRS-4508 tablet target?
Related
- Drug class: All Small molecule drugs
- Target: All drugs targeting Unknown
- Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Unknown
- Indication: Drugs for Unknown
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing